Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Rooney

Showing results (91-100 of 165) with videos related to

Pageof 17
Sort By:
AIDS (London, England)|July 16, 2014
Successful antiretroviral therapy delivery and retention in care among asymptomatic individuals with high CD4+ T-cell counts above 350 cells/μl in rural UgandaVivek Jain, Dathan M Byonanebye, Gideon Amanyire, et al.
The Journal of Antimicrobial Chemotherapy|April 4, 2017
Single-dose pharmacokinetics of tenofovir alafenamide and its active metabolite in the mucosal tissuesMackenzie L Cottrell, Katy L Garrett, Heather M A Prince, et al.
AIDS (London, England)|February 14, 2006
Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected womenKenneth H Mayer, Lisa A Maslankowski, Fang Gai, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 1, 2025
Bone Changes With Long-Acting Cabotegravir or Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Prevention in Cisgender Men and Transgender Women: HPTN 083Todd T Brown, Robert F Arao, Maryam Warsi, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 17, 2008
The pharmacokinetics and viral activity of tenofovir in the male genital tractManoli Vourvahis, Hiba L Tappouni, Kristine B Patterson, et al.
Journal of Clinical Pathology|June 11, 2025
Use of DNA profiling to resolve HIV status in a person using injectable cabotegravir for HIV pre-exposure prophylaxisJessica M Fogel, M Ali Salih, Kathy Haddaway, et al.
BMC Public Health|May 27, 2011
Asking the right questions: developing evidence-based strategies for treating HIV in women and childrenQuarraisha Abdool Karim, Anchilla Banegura, Pedro Cahn, et al.
Plos One|October 3, 2013
Safety, adherence and acceptability of intermittent tenofovir/emtricitabine as HIV pre-exposure prophylaxis (PrEP) among HIV-uninfected Ugandan volunteers living in HIV-serodiscordant relationships: a randomized, clinical trialFreddie M Kibengo, Eugene Ruzagira, David Katende, et al.
AIDS Care|March 22, 2019
Effective use of pre-exposure prophylaxis (PrEP) Among stimulant users with multiple condomless sex partners: a longitudinal study of men who have sex with men in Los AngelesDavid Goodman-Meza, Matthew R Beymer, Ryan M Kofron, et al.
AIDS (London, England)|May 7, 2009
Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatmentRichard H Haubrich, Sharon A Riddler, A Gregory DiRienzo, et al.
Pageof 17

Showing results (91-100 of 165) with videos related to

Sort By:
Pageof 17
AIDS (London, England)|July 16, 2014
Successful antiretroviral therapy delivery and retention in care among asymptomatic individuals with high CD4+ T-cell counts above 350 cells/μl in rural UgandaVivek Jain, Dathan M Byonanebye, Gideon Amanyire, et al.
The Journal of Antimicrobial Chemotherapy|April 4, 2017
Single-dose pharmacokinetics of tenofovir alafenamide and its active metabolite in the mucosal tissuesMackenzie L Cottrell, Katy L Garrett, Heather M A Prince, et al.
AIDS (London, England)|February 14, 2006
Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected womenKenneth H Mayer, Lisa A Maslankowski, Fang Gai, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 1, 2025
Bone Changes With Long-Acting Cabotegravir or Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Prevention in Cisgender Men and Transgender Women: HPTN 083Todd T Brown, Robert F Arao, Maryam Warsi, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 17, 2008
The pharmacokinetics and viral activity of tenofovir in the male genital tractManoli Vourvahis, Hiba L Tappouni, Kristine B Patterson, et al.
Journal of Clinical Pathology|June 11, 2025
Use of DNA profiling to resolve HIV status in a person using injectable cabotegravir for HIV pre-exposure prophylaxisJessica M Fogel, M Ali Salih, Kathy Haddaway, et al.
BMC Public Health|May 27, 2011
Asking the right questions: developing evidence-based strategies for treating HIV in women and childrenQuarraisha Abdool Karim, Anchilla Banegura, Pedro Cahn, et al.
Plos One|October 3, 2013
Safety, adherence and acceptability of intermittent tenofovir/emtricitabine as HIV pre-exposure prophylaxis (PrEP) among HIV-uninfected Ugandan volunteers living in HIV-serodiscordant relationships: a randomized, clinical trialFreddie M Kibengo, Eugene Ruzagira, David Katende, et al.
AIDS Care|March 22, 2019
Effective use of pre-exposure prophylaxis (PrEP) Among stimulant users with multiple condomless sex partners: a longitudinal study of men who have sex with men in Los AngelesDavid Goodman-Meza, Matthew R Beymer, Ryan M Kofron, et al.
AIDS (London, England)|May 7, 2009
Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatmentRichard H Haubrich, Sharon A Riddler, A Gregory DiRienzo, et al.
Pageof 17